Phase 4 Atrial Fibrillation Trial, Recruiting NCT04700826 Sponsor: University of Birmingham Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 4 Atrial Fibrillation Trial, Recruiting

NCT04700826
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with atrial fibrillation (an irregular heartbeat condition) — whether in the past, currently, or as an ongoing condition
  • People who are aged between 55 and 73 years old at the time of joining the trial

Who may not be able to join:

  • People who have previously had a stroke, a mini-stroke (also called a transient ischaemic attack), or a blood clot that travelled to another part of the body
  • People who have a combination of multiple known stroke risk factors — such as heart failure, high blood pressure, being aged 65 or older, diabetes, a previous heart attack, circulation problems in the legs or major blood vessels, and/or being female — where a doctor would normally start blood-thinning medication
  • People who have ever had bleeding inside the brain
  • People who have had a serious bleeding event requiring a hospital stay within the last 3 years
  • People who have had a condition in the last 12 months that raises the risk of serious bleeding, such as stomach ulcers, certain brain or eye injuries or surgeries, abnormal blood vessels, liver disease affecting blood clotting, varicose veins in the food pipe, or certain cancers (confirm with trial site)
  • People whose kidneys are not working well enough, based on a blood test result from the last 12 months
  • People who have taken certain antifungal medications (ketoconazole, itraconazole, voriconazole, or posaconazole) in the last 3 months
  • People who have a documented diagnosis of dementia
  • People who have had an allergic reaction to or cannot tolerate blood-thinning tablets of the type known as direct oral anticoagulants
  • People who are currently taking any blood-thinning medication
  • People who have any medical reason that means a doctor has recommended they take blood-thinning medication
  • People who are currently experiencing active, significant bleeding
  • People whose life expectancy is estimated to be less than 2 years
  • People who are unwilling or unable to give consent for their electronic health records to be accessed and linked for the trial
  • People who are currently taking part in another clinical trial
  • Women who could become pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Dipak Kotecha, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust

Phone: +44 121 371 4225

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
University of Birmingham
Registry
ClinicalTrials.gov
Start date
1 June 2021
Est. completion
1 December 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Composite primary endpoint - Time to first event

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov